Drug distributor McKesson and private equity firm Clayton Dubilier & Rice agreed October 6 to take infusion therapy provider Option Care Health private in a transaction valued at $5.8 billion. The deal marks one of the largest healthcare take-privates this year and positions McKesson deeper into specialty care delivery, an area where reimbursement pressures have made public markets inhospitable.
Option Care operates over 100 infusion centers across the United States, treating patients with chronic conditions through home and ambulatory infusion services. The company reported $4.7 billion in revenue for the twelve months ending June 2026, with margins compressed by labor costs and payer mix deterioration. Its stock had traded sideways since early 2025, reflecting investor fatigue with the sector's operational complexity. McKesson's partnership with CD&R structures the transaction as a joint acquisition rather than a pure PE rollup, suggesting the distributor sees infusion as a long-term adjacency rather than a financial engineering opportunity.
This matters because infusion therapy sits at the intersection of three trends allocators are tracking: specialty drug distribution, site-of-care shifts, and vertical integration by large intermediaries. McKesson already moves one-third of all pharmaceuticals in North America. Adding Option Care's delivery infrastructure gives it direct patient touchpoints in high-cost therapy categories—oncology, immunology, antivirals—where payers are pushing treatment out of hospitals and into lower-cost settings. CD&R brings operational expertise from prior healthcare services investments, but McKesson's willingness to split ownership signals confidence that infusion networks will remain strategic assets as biosimilars and cell therapies scale over the next five years.
The transaction also reflects a broader reset in healthcare services valuations. Option Care traded at roughly 0.9x trailing revenue before the announcement, well below the 1.4x multiples specialty pharmacy peers commanded in 2023. Private equity has stepped into this valuation gap across home health, infusion, and dialysis over the past eighteen months, betting that operational improvements and reimbursement stabilization will unlock value public markets refuse to price. McKesson's participation suggests corporates are now competing for these assets, not waiting for PE to flip them back. That changes the risk profile for minority investors in similar public comps—if a strategic buyer sees multi-year value, the takeout floor rises.
Operators should watch for regulatory filings by mid-November, which will clarify governance splits and financing sources. McKesson has $3.2 billion in cash and short-term investments as of its last quarter, so leverage structure will signal how aggressively CD&R plans to optimize the capital base. Allocators with exposure to specialty pharmacy equities—particularly those in home infusion or specialty distribution—should revisit comp multiples, as this sets a precedent for how large distributors value last-mile delivery assets. Any follow-on deals in ambulatory infusion or home health in Q4 2026 or Q1 2027 will confirm whether this is a one-off partnership or the start of a consolidation wave.
The transaction closes the gap between pharmaceutical distribution and direct patient services, a boundary that has blurred steadily since McKesson invested in oncology networks five years ago. CD&R's track record in operational turnarounds means Option Care will likely face workforce restructuring and center consolidation within eighteen months. The fact that McKesson chose to partner rather than acquire outright tells you everything about the risk it perceives in infusion reimbursement—and everything about the value it sees if those risks resolve.
The takeaway
$5.8B take-private by McKesson and CD&R signals distributor-to-delivery integration and resets specialty care service valuations.
Editorial & Disclosure Notice: This article was written with artificial intelligence from public sources and is published without individual human review. Artificial intelligence and other digital tools are also used for research, analysis, editing, formatting, and production. Errors, omissions, outdated information, or inaccuracies may occur. References to companies, brands, products, services, organizations, or individuals are for informational and editorial purposes and do not imply endorsement, sponsorship, affiliation, partnership, or approval unless expressly stated. All trademarks and other intellectual property remain the property of their respective owners. Opinions, analysis, estimates, and commentary are informational only and should not be construed as financial, investment, legal, tax, medical, procurement, or other professional advice. Information may be corrected, clarified, or updated after publication. Corrections or removal requests: jenny@pops4.com.
Want the 60-second program for your specific event?
Enter your event and email — we build it and send the branded proposal before lunch. No obligation.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.